755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H).

Saved in:
Bibliographic Details
Title: 755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H).
Authors: Berton-Rigaud, D.1 (AUTHOR), Pautier, P.2 (AUTHOR), Lorusso, D.3 (AUTHOR), Gennigens, C.4 (AUTHOR), Gladieff, L.5 (AUTHOR), Kryzhanivska, A.6 (AUTHOR), Bowman, J.7 (AUTHOR), Tian, C.8 (AUTHOR), Cornfeld, M.7 (AUTHOR), Van Gorp, T.9 (AUTHOR)
Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS517-S517. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2023.09.1934